Tamara Intermesoli

3.3k total citations
46 papers, 1.0k citations indexed

About

Tamara Intermesoli is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Genetics. According to data from OpenAlex, Tamara Intermesoli has authored 46 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Hematology, 29 papers in Public Health, Environmental and Occupational Health and 22 papers in Genetics. Recurrent topics in Tamara Intermesoli's work include Acute Lymphoblastic Leukemia research (29 papers), Chronic Myeloid Leukemia Treatments (27 papers) and Chronic Lymphocytic Leukemia Research (21 papers). Tamara Intermesoli is often cited by papers focused on Acute Lymphoblastic Leukemia research (29 papers), Chronic Myeloid Leukemia Treatments (27 papers) and Chronic Lymphocytic Leukemia Research (21 papers). Tamara Intermesoli collaborates with scholars based in Italy, Germany and United Kingdom. Tamara Intermesoli's co-authors include Alessandro Rambaldi, Josée Golay, Martino Introna, Elisa Gotti, Luca Bologna, Orietta Spinelli, Renato Bassan, Massimiliano Manganini, Giuseppe Rossi and Elena Oldani and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Tamara Intermesoli

42 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tamara Intermesoli Italy 17 575 460 331 222 214 46 1.0k
Maurizio Miglino Italy 18 737 1.3× 206 0.4× 260 0.8× 99 0.4× 319 1.5× 65 1.1k
Loredana Elia Italy 18 1.1k 1.9× 1.3k 2.7× 263 0.8× 196 0.9× 466 2.2× 35 1.6k
Maria Stefania De Propris Italy 19 398 0.7× 230 0.5× 436 1.3× 343 1.5× 274 1.3× 54 1.0k
S. E. Sallan United States 11 290 0.5× 585 1.3× 206 0.6× 151 0.7× 131 0.6× 16 1.1k
Monica Kwari United States 16 1.2k 2.0× 896 1.9× 433 1.3× 249 1.1× 567 2.6× 47 1.7k
Deborah Thomas United States 13 997 1.7× 760 1.7× 453 1.4× 146 0.7× 288 1.3× 19 1.3k
Marie Jarošová Czechia 17 354 0.6× 108 0.2× 301 0.9× 156 0.7× 136 0.6× 87 766
Kendra Sweet United States 22 1.1k 2.0× 170 0.4× 604 1.8× 180 0.8× 647 3.0× 180 1.8k
Vladan Vučinić Germany 18 518 0.9× 172 0.4× 153 0.5× 148 0.7× 333 1.6× 105 934
Wolf‐Dieter Ludwig Germany 15 481 0.8× 455 1.0× 157 0.5× 424 1.9× 276 1.3× 25 1.0k

Countries citing papers authored by Tamara Intermesoli

Since Specialization
Citations

This map shows the geographic impact of Tamara Intermesoli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tamara Intermesoli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tamara Intermesoli more than expected).

Fields of papers citing papers by Tamara Intermesoli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tamara Intermesoli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tamara Intermesoli. The network helps show where Tamara Intermesoli may publish in the future.

Co-authorship network of co-authors of Tamara Intermesoli

This figure shows the co-authorship network connecting the top 25 collaborators of Tamara Intermesoli. A scholar is included among the top collaborators of Tamara Intermesoli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tamara Intermesoli. Tamara Intermesoli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Iurlo, Alessandra, Cristina Bucelli, Tamara Intermesoli, et al.. (2024). Bosutinib Treatment of Chronic Myeloid Leukemia in Lombardy. Acta Haematologica. 148(4). 494–498. 1 indexed citations
3.
Breccia, Massimo, Alfonso Piciocchi, Elisabetta Abruzzese, et al.. (2023). Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey. Journal of Clinical Medicine. 12(16). 5267–5267. 1 indexed citations
4.
Intermesoli, Tamara, et al.. (2022). Lymphoblastic Lymphoma: a Concise Review. Current Oncology Reports. 24(1). 1–12. 15 indexed citations
5.
Tosi, Manuela, Orietta Spinelli, Matteo Leoncin, et al.. (2021). MRD-Based Therapeutic Decisions in Genetically Defined Subsets of Adolescents and Young Adult Philadelphia-Negative ALL. Cancers. 13(9). 2108–2108. 5 indexed citations
6.
Sommer, Kathrin, Marco Vignetti, Francesco Cottone, et al.. (2020). Acute promyelocytic leukaemia long-term survivors: higher fatigue and greater overall symptom burden. BMJ Supportive & Palliative Care. 12(2). 182–186. 2 indexed citations
7.
Gemelli, Maria, Elena Maria Elli, Chiara Elena, et al.. (2020). Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study. Blood Research. 55(3). 139–145. 6 indexed citations
8.
9.
Efficace, Fabio, Massimo Breccia, Giuseppe Avvisati, et al.. (2018). Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia. Leukemia. 33(7). 1598–1607. 20 indexed citations
10.
Lussana, Federico, et al.. (2017). Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia. Handbook of experimental pharmacology. 249. 231–250. 20 indexed citations
11.
Graffigna, Guendalina, Massimo Breccia, Enrico Capochiani, et al.. (2017). Recovering from chronic myeloid leukemia: the patients’ perspective seen through the lens of narrative medicine. Quality of Life Research. 26(10). 2739–2754. 20 indexed citations
12.
Bassan, Renato, Tamara Intermesoli, Piera Viero, et al.. (2017). Minimal Residual Disease Assessment and Risk-based Therapy in Acute Lymphoblastic Leukemia. Clinical Lymphoma Myeloma & Leukemia. 17. S2–S9. 18 indexed citations
13.
Iurlo, Alessandra, Umberto Gianelli, Alessandro Beghini, et al.. (2014). Identification of kitM541L somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response. Oncotarget. 5(13). 4665–4670. 23 indexed citations
14.
Intermesoli, Tamara, Alessandro Rambaldi, Giuseppe Rossi, et al.. (2013). High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program. Haematologica. 98(11). 1718–1725. 34 indexed citations
15.
Bassan, Renato, Tamara Intermesoli, Orietta Spinelli, Elena Oldani, & Alessandro Rambaldi. (2012). Modern therapy of young and adult Ph-ALL. PubMed. 1(S2). S5–S6. 2 indexed citations
16.
Cortelazzo, Sergio, Tamara Intermesoli, Elena Oldani, et al.. (2011). Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma. Annals of Hematology. 91(1). 73–82. 28 indexed citations
17.
18.
Intermesoli, Tamara, Jonathan Shamash, A. Z. S. Rohatiner, et al.. (2009). Low dose continuous chemotherapy (LD56): an active treatment with low toxicity for patients with recurrent/refractory lymphoma not eligible for intensive salvage therapy. British Journal of Haematology. 147(3). 408–410. 1 indexed citations
19.
Bassan, R, Tamara Intermesoli, Elena Oldani, et al.. (2008). Short-course imatinib (IM) added to chemotherapy improves early but not long-term outcome in adult Ph/BCR-ABL+ acute lymphoblastic leukemia (ALL) : 5-year follow-up results of study NILG-09. Haematologica. 93. 366–367. 4 indexed citations
20.
Spinelli, Orietta, Barbara Peruta, Vittoria Guerini, et al.. (2007). Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica. 92(5). 612–618. 96 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maurizio Miglino Breakdown of academic impact, for papers by Loredana Elia Breakdown of academic impact, for papers by Maria Stefania De Propris Breakdown of academic impact, for papers by S. E. Sallan Breakdown of academic impact, for papers by Monica Kwari Breakdown of academic impact, for papers by Deborah Thomas Breakdown of academic impact, for papers by Marie Jarošová Breakdown of academic impact, for papers by Kendra Sweet Breakdown of academic impact, for papers by Vladan Vučinić Breakdown of academic impact, for papers by Wolf‐Dieter Ludwig
Rankless by CCL
2026